Journal article

Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers

Ingo Ahrens, Meike Schwarz, Karlheinz Peter, Christoph Bode

TRANSFUSION MEDICINE AND HEMOTHERAPY | KARGER | Published : 2007

Abstract

A variety of orally and intravenously administered agents have been made available for anti-platelet therapy. Clinical trials in patients with acute manifestations of cardiovascular disease have shown that the combined administration of substances which inhibit different steps of platelet adhesion and aggregation reduce cardiovascular adverse events. However, the risk of bleeding may increase depending on the patient's comorbidity, age and the agents that are used for concomitant anticoagulation. Therefore, ongoing efforts are made to develop highly effective inhibitors of platelet function with an excellent controllability and the lowest acceptable risk of bleeding events. The current pharm..

View full abstract